k 13

K-13 is used as an ACE inhibitor produced by Micromonospora halophytics subsp. exilisia K-13.

K 13-004 is a lipid-lowering agent.

8K13-hz35-STING-D4-1203 is an ADC (antibody-drug conjugate) linker compound.

PI3K/mTOR Inhibitor-13, an orally active dual inhibitor targeting phosphoinositol 3-kinase (PI3K) and mTOR kinase, holds potential for treating sexual diseases, solid tumors, and idiopathic pulmonary fibrosis (IPF).

PI3Kα-IN-13 (Compound 18a), a PI3Kα inhibitor with an IC50 of 2.5 nM, effectively induces apoptosis and hampers the proliferation of various cancer cell lines, exhibiting IC50 values of 0.75 μM (MCF-7), 3.79 μM (HCT-116), 13.71 μM (MDA-MB-231), and 9.85 μM (SW620). This compound also impedes tumor cell colony formation, migration, and invasion [1].

ZK 136295 is a novel estrogen. When taken orally, it shows reduced systemic availability and high variability similar to ethinylestradiol. Doubling the dose of ZK 136295 can increase its systemic availability, emphasizing the importance of dosage in enhancing bioavailability.

PK 130, as a hypoxic cell radiosensitizer, is an L-phenylalanine methyl ester conjugate of 2-nitroimidazol.

IEIK 13, a self-assembling peptide (SAP), is employed in cartilage tissue engineering research [1].

TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.

Lanopepden (GSK 1322322) is a potent peptide deformylase inhibitor effective against Staphylococcus aureus strains ATCC 29213 and ATCC 25923, and is applicable in the study of pneumonia, dermatological, and infectious diseases.

Lanopepden mesylate is a peptide deformylase inhibitor against Staphylococcus aureus.

C 101248 (KCNK13-IN-1) is a selective and potent tandem pore halogen inhibitor of K+ channel 1 (THIK-1) inhibitor and human and mouse KCNK13 inhibitor.C 101248 inhibits IL-1β release in a concentration-dependent manner and can be used for the study of inflammation induced by neurodegenerative disorders.

Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

EUK-134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities and inhibits the formation of β-amyloid and related amyloid fibrils.

BDM31343, an EthR inhibitor in Mycobacterium tuberculosis, enhances the antimicrobial activity of ethionamide with nanomolar potency, while improving solubility and metabolic stability.

MAPK13-IN-1 is a potent MAPK13 (p38δ) inhibitor (IC50: 620 nM).

Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or liver metastasis on T1-weighted imaging. It is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system. It accumulates in normal, fun

GSK1379725A is a selective BPTF ligand [Kd = 2.8 μM].

K134 is an inhibitor of phosphodiesterase 3. The IC50s of K134 for PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively.

K13787 is an acetohydroxy acid synthase (AHAS) inhibitor with antibacterial properties. It exhibits antimicrobial activity against various non-tuberculous mycobacteria (NTM) as well as clarithromycin (CLR) resistant strains.

VK13 (Compound 6) is a potent inhibitor of human cathepsin L (hCatL) and SARS-CoV-2 3CLpro (3CL-PR), with Ki values of 2.6 nM and 0.55 nM, respectively. It also exhibits activity against CoV-2, with an EC50 value of 1.25 μM.

CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.

CDK12/13-IN-3 (Compound 12b) is an orally active CDK inhibitor targeting CDK12 and CDK13, with IC50 values of 107.4 nM and 79.4 nM, respectively. This compound inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression involved in the DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative effects against various cancer cells with nanomolar IC50 values. In mouse models, it demonstrates antitumor activity, favorable pharmacokinetic properties, and an oral bioavailability of 53.6%.